Zobrazeno 1 - 10
of 44
pro vyhledávání: '"James R Runo"'
Autor:
Krista L Lentice, Deborah J Levine, James R Runo, Yasar Caliskan, Salvatore P Costa, Ngan N Lam, David A Axelrod, Kenneth J Woodside
Publikováno v:
Turkish Journal of Nephrology, Vol 33, Iss 1, Pp 8-26 (2024)
Externí odkaz:
https://doaj.org/article/588c1c3af3d647c18ec4bbcd1ea77af0
Autor:
Hilary M. DuBrock, Charles D. Burger, Sonja D. Bartolome, Jeremy P. Feldman, D. Dunbar Ivy, Erika B. Rosenzweig, Jeffrey S. Sager, Kenneth W. Presberg, Stephen C. Mathai, Matthew R. Lammi, James R. Klinger, Michael Eggert, Teresa De Marco, Jean M. Elwing, David Badesch, Todd M. Bull, Linda M. Cadaret, Gautam Ramani, Thenappan Thenappan, H. James Ford, Nadine Al-Naamani, Marc A. Simon, Sula Mazimba, James R. Runo, Murali Chakinala, Evelyn M. Horn, John J. Ryan, Robert P. Frantz, Michael J. Krowka
Publikováno v:
Pulmonary Circulation, Vol 11 (2021)
Compared to idiopathic pulmonary arterial hypertension (IPAH), patients with portopulmonary hypertension (POPH) have worse survival. Health disparities may contribute to these differences but have not been studied. We sought to compare socioeconomic
Externí odkaz:
https://doaj.org/article/0eb2fcb1424a48d382c3a48edad8720f
Autor:
Hilary M. DuBrock, MD, James R. Runo, MD, Corey J. Sadd, MD, Charles D. Burger, MD, Rodrigo Cartin-Ceba, MD, Charles B. Rosen, MD, Timucin Taner, MD, PhD, Scott L. Nyberg, MD, PhD, Julie K. Heimbach, MD, James Y. Findlay, MB, CHB, Michael J. Krowka, MD
Publikováno v:
Transplantation Direct, Vol 6, Iss 12, p e630 (2020)
Background. Portopulmonary hypertension (POPH), pulmonary arterial hypertension (PAH) that develops in the setting of portal hypertension, affects 5%–6% of patients with liver disease and is associated with significant morbidity and mortality. A me
Externí odkaz:
https://doaj.org/article/2dc69ef20740460b9cba137975d3c8b3
Autor:
Omid Forouzan, Eric Dinges, James R. Runo, Jonathan G. Keevil, Jens C. Eickhoff, Christopher Francois, Naomi C. Chesler
Publikováno v:
Frontiers in Physiology, Vol 10 (2019)
Background: Pulmonary hypertension causes pulmonary artery (PA) stiffening, which overloads the right ventricle (RV). Since symptoms of pulmonary hypertension (PH) are exacerbated by exercise, exercise-induced PA stiffening is relevant to cardiopulmo
Externí odkaz:
https://doaj.org/article/99d1bd9fb4cc43e7b49bd93e9e9a86a0
Publikováno v:
Chest. 160:e205-e208
Case Presentation A 48-year-old man presented with 6 months of progressive shortness of breath, intermittent exertional left-sided chest pain, and bilateral lower extremity edema. During the 2 days before admission, he experienced new onset confusion
Publikováno v:
Pulmonary Circulation. 12
There is little known about performing transcatheter aortic valve replacement (TAVR) in patients with group 1 pulmonary arterial hypertension (PAH) on advanced pulmonary vasodilator therapy. Retrospective cohort study among 90 patients with systemic
Autor:
Naomi C. Chesler, Joanna Eva Kusmirek, Aurangzeb Baber, James R. Runo, Christopher J. François, Nizar N. Jarjour, Sofia Carolina Masri, Marlowe W. Eldridge, Farhan Raza, Ravi Dhingra, Roderick C. Deaño, Ran Tao, Zuzana Burivalova, Naga Dharmavaram, Rebecca Vanderpool, Timothy Hess
Publikováno v:
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, vol 74, iss 1
Background Right ventricular (RV) dilation has been used to predict adverse outcomes in acute pulmonary conditions. It has been used to categorize the severity of novel coronavirus infection (COVID-19) infection. Our study aimed to use chest CT-angio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5026476d4741bb98ca93d3718ff958ff
https://escholarship.org/uc/item/8mr6977z
https://escholarship.org/uc/item/8mr6977z
Autor:
Marlowe W. Eldridge, Farhan Raza, James R. Runo, Theodore J. Berei, Naomi C. Chesler, Callyn Kozitza, Amy Chybowski, Kara N. Goss
Publikováno v:
JACC Case Reports
A 48-year-old woman who had been receiving long-term interferon-β for 8 years for multiple sclerosis developed drug-induced World Health Organization group I pulmonary arterial hypertension. Triple therapy for pulmonary arterial hypertension and sus
Autor:
Jacqueline T. DesJardin, Nicholas A. Kolaitis, Noah Kime, Richard A. Kronmal, Raymond L. Benza, Jean M. Elwing, Matthew R. Lammi, John W. McConnell, Kenneth W. Presberg, Jeffrey S. Sager, Oksana A. Shlobin, Teresa De Marco, Roblee Allen, David Badesch, Sahil Bakshi, Sonja Bartolome, TM Bull, Charles D Burger, Linda M Cadaret, Murali Chakinala, Michael Duncan, Michael Eggert, Jeremy Feldman, Jeff Fineman, Raymond J. Foley, Hubert James Ford, Robert P Frantz, Daniel Grinnan, Anna R Hemnes, Russel Hirsch, Evelyn M Horn, D Dunbar Ivy, Steven M Kawut, James R Klinger, Peter J Leary, Stephen C Mathai, Sula Mazimba, Kishan S Parikh, Kenneth W Presberg, Amresh Raina, Gautam Ramani, Jeffrey C Robinson, Erika B Rosenzweig, James R Runo, John J Ryan, Jeffrey S Sager, Oksana A Shlobin, Marc A Simon, John W Swisher, Thenappan Thenappan, Nidhy P Varghese, Corey E Ventetuolo, R. James White, Timothy Williamson, Delphine Yung, Roham T Zamanian, Dianne L Zwicke
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:945-953
BACKGROUND The age of patients with pulmonary arterial hypertension (PAH) has increased, with registries now reporting mean ages of 50 to 65 years old. Limited data exist on age-related differences in hemodynamic and functional assessments in PAH. ME
Autor:
Catherine Decker, Laura L. Hammel, Amy Chybowski, Zhanhai Li, Fauzia Osman, Bruce Henderson, Corey J. Sadd, James R. Runo, Kara N. Goss
Publikováno v:
Transplantation. 105:346-353
Background Portopulmonary hypertension is present in an estimated 5.3% to 8.5% of liver transplant candidates. Untreated, 5-year survival is estimated between 14% and 28%. Moderate-severe disease is a contraindication to liver transplant due to the h